| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | Entrez:1489668 - | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | spike glycoprotein | |||||
| GTO ID | GTC2628 |
| Trial ID | NCT04805216 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;ChAdOx1-S Vaccine|Astra Zeneca Vaccine;COVID-19 mRNA Vaccine|Moderna Vaccine |
| Co-treatment | Blood test |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;NULL;US, Canada, Israel, EU, Switzerland, Singapore, Qatar, Vietnam, UK, Philippines, Thailand, Japan, South Korea, Brunei, Paraguay, China, Botswana, India, Indonesia, Saudi Arabia, Mexico, Australia, Nigeria, Colombia |
| Recruitment status | Completed |
| Title | A Single-centre, Observational Study to Evaluate Immune Response to Covid-19 Vaccines in Immunocompromised Patients With Haematological Disorders |
| Year | 2021 |
| Country | United Kingdom |
| Company sponsor | University Hospitals of North Midlands NHS Trust |
| Other ID(s) | 3025 |
| Cohort1: Immunocompromised patients | |||||
|
|||||
| Cohort2: Immunocompetent volunteers | |||||
|
|||||